Health TrialsbyHealthPanel

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

PRA-216 Atopic Dermatitis Safety and Efficacy Study

This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)

Participants needed: 39
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Prana Therapies IncUpdated: Sep 9, 2026Locations: 8
Eligibility criteria

Must be in good health with no significant medical history [+4]

Evidence of clinically significant skin condition or disease other than AD [+5]

Read more
Status: Recruiting

Study of PRA-216 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Phase 1 of this study will consist of 2 parts * Part 1 will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 in healthy volunteers through single ascending dose administered by either intravenous (IV) or subcutaneous (SC). * Part 2 will evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of PRA-216 in healthy volunteers with repeat doses of multiple ascending dose administered subcutaneously. Phase 2a of this study is a randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and immunogenicity of PRA-216 in participants with mild to moderate asthma. The dose of PRA-216 for this phase was determined from Phase 1.

Participants needed: 96
Trial details
Phase: Phase 1, Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Prana Therapies IncUpdated: Aug 6, 2026Locations: 8
Eligibility criteria

Age 18-65 [+3]

Evidence of clinically significant condition or disease [+18]

Read more
Status: Not yet recruiting

PRA-216 COPD Safety and Biomarker Study

This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).

Participants needed: 40
Trial details
Phase: Phase 2Age: 40-80Biological sex: AllType: InterventionalSponsor: Prana Therapies IncUpdated: Jul 28, 2026
Eligibility criteria

Age 40-80 [+4]

Evidence of clinically significant pulmonary condition or disease other than COP... [+6]

Read more